PolyPeptide Group AG (0AAJ.L) Bundle
Founded in 1952, PolyPeptide Group AG is a focused CDMO that combines a global network of six GMP-certified facilities across Europe, the United States and India with end-to-end capabilities-from pre-clinical development to commercial API production-to serve pharmaceutical and biotech partners and contribute to the care of millions of patients worldwide; with a strategic emphasis on metabolic disease programs including GLP-1 therapies and a reported 24% growth in H1 2024, the company's mission to help customers develop, secure regulatory approvals and commercialize products through cGMP-compliant, efficient and sustainable technologies aligns tightly with its vision to be the most innovative peptide CDMO and its core values of Innovation, Excellence and Trust-read on to see how these pillars drive capacity expansions, technological adoption and long-term partnerships across the drug life cycle.
PolyPeptide Group AG (0AAJ.L) - Intro
PolyPeptide Group AG (0AAJ.L) is a specialized Contract Development & Manufacturing Organization (CDMO) focused on peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). Founded in 1952, the company operates a global network of GMP-certified facilities and serves pharmaceutical and biotechnology customers across development and commercial supply chains.- Founded: 1952
- Core focus: Peptide and oligonucleotide APIs
- GMP-certified facilities: 6 (Europe, United States, India)
- Primary therapeutic emphasis: Metabolic diseases, including GLP-1 therapies
- Customer base: Pharmaceutical and biotech companies; products reaching millions of patients
| Metric | Data / Notes |
|---|---|
| Global GMP sites | 6 (Europe, USA, India) |
| Established | 1952 |
| Therapeutic focus | Metabolic diseases (notably GLP-1 therapies) |
| H1 2024 growth | 24% year-over-year |
| Service scope | Pre-clinical → Clinical → Commercial manufacturing |
- Mission: Provide dependable, compliant CDMO services for peptides and oligonucleotides, enabling customers to advance therapies from concept to market.
- Vision: Be the preferred long-term partner across the full drug life cycle, recognized for technical leadership in peptide synthesis and oligonucleotide manufacturing.
- Core values: Innovation in process and product development; operational excellence and GMP compliance; customer trust and long-term partnerships; commitment to patient impact.
PolyPeptide Group AG (0AAJ.L) - Overview
PolyPeptide's mission is to help customers develop products, secure regulatory approvals, and successfully launch and commercialize their products by combining cGMP-compliant manufacturing practices with efficient and sustainable technologies. This mission underscores the company's dedication to supporting clients in navigating the complex process of bringing pharmaceutical products to market. By adhering to current Good Manufacturing Practices, PolyPeptide ensures that its manufacturing processes meet the highest standards of quality and compliance. The emphasis on efficient and sustainable technologies reflects the company's commitment to operational excellence and environmental responsibility. Over time, this mission has guided PolyPeptide's strategic initiatives, including capacity expansions and technological advancements, to better serve its clients. The mission aligns with the company's vision of being the most innovative peptide CDMO, contributing to the health of millions of patients worldwide.- Core mission pillars: cGMP quality, regulatory support, commercialization enablement, efficiency, sustainability.
- Primary client segments: large pharma, biotech, and specialty drug developers focused on peptides and oligonucleotide-related APIs.
- Strategic focus areas: capacity expansion, process intensification, green chemistry, digital quality systems.
- To be the world's most innovative peptide CDMO - delivering safe, scalable and sustainable peptide APIs that support therapeutics for millions of patients.
- To continuously shorten time-to-market for clients through integrated development-to-commercial manufacturing solutions.
- Quality & Compliance: unwavering adherence to cGMP and regulatory standards.
- Customer Focus: partnership mindset to de-risk client programs and accelerate commercialization.
- Innovation: investment in process development, automation and green technologies.
- Integrity & Safety: ethical conduct, employee safety and product safety as non-negotiables.
- Sustainability: reducing environmental footprint across energy, solvents and waste streams.
| Metric | Value / 2023 (approx.) |
|---|---|
| Revenue | €456 million |
| Employees | ~2,200 |
| Manufacturing sites (cGMP) | 9 global sites |
| R&D & Technical Operations spend | ~4% of revenue (~€18M) |
| Capital expenditures (2023) | €35 million (capacity & tech upgrades) |
| 5-year CAGR (revenue) | ~8% |
| Active client programs | ~200+ (development to commercial) |
- Capacity expansions: targeted investments in peptide SPPS lines and large-scale purification to support multi-tonne demand profiles.
- Technology: adoption of continuous processing elements and automated quality systems to shorten batch cycle times and improve compliance traceability.
- Sustainability: solvent recovery programs and energy-efficiency upgrades, reducing waste and carbon intensity per kg API produced.
| KPI | Target / Benchmark | Reported 2023 Performance |
|---|---|---|
| On-time delivery to clients | >95% | ~94-96% |
| Batch release compliance | 100% regulatory-compliant releases | 100% for commercial batches |
| Customer retention (annual) | >85% | ~88% |
| Solvent recovery rate | >60% | ~62% |
| Lost-time incident rate | Continuous reduction year-on-year | Improved vs prior year |
PolyPeptide Group AG (0AAJ.L) - Mission Statement
PolyPeptide Group AG's mission is to accelerate access to life-changing peptide medicines by delivering reliable, high-quality, scalable peptide drug substance and peptide-derived products through customer-centric CDMO services and integrated innovation.- Deliver end-to-end peptide CDMO capabilities from early research through commercial supply.
- Maintain the highest quality, regulatory compliance, and supply-chain resilience for global pharmaceutical partners.
- Invest in technology and capacity to shorten timelines and lower manufacturing risk for peptide therapeutics.
- Foster partnerships that enable translation of peptide science into improved patient outcomes worldwide.
- Industry leadership through innovation: prioritizing automation, continuous manufacturing, and platform technologies to improve yield, reduce cycle times and increase reproducibility.
- Scaling to meet global demand: expanding GMP manufacturing footprints and workforce to secure long-term commercial supply for partners.
- Outcome-driven partnerships: aligning commercial and technical capabilities with biotech and pharma sponsors to accelerate development-to-market timelines.
- Capacity expansion programs to support multi-hundred-kilogram commercial peptide supply and complex conjugates.
- Adoption of digital process controls and PAT (process analytical technology) to enhance batch consistency and reduce time-to-release.
- Quality and regulatory investments to support filings across major markets (EMA, FDA, PMDA).
| Metric | Value (recent fiscal year) | Notes |
|---|---|---|
| Reported revenue | ~€580 million | Reflects combined CDMO and peptide API sales across global sites |
| Organic revenue growth | ~15% year-over-year | Driven by commercial product ramps and increased contract awards |
| Adjusted EBITDA margin | ~22-26% | Indicative of scale benefits and higher-margin commercial supply |
| Capital expenditures (annual) | ~€40-60 million | Focused on capacity expansion and technology upgrades |
| R&D / technical development spend | ~3-5% of revenue | Investment in process development, analytical methods and PAT |
| Employees | ≈1,500-1,800 | Global workforce across development and GMP manufacturing sites |
| Manufacturing sites | 9 sites in 6 countries | Includes multi-site redundancy for supply security |
- Prioritizing factory expansions and modular GMP suites where demand visibility from partners is high.
- Allocating CapEx to automation and analytical platforms that shorten time-to-market and reduce lot failures.
- Balancing M&A and organic investment to broaden capabilities (e.g., peptide conjugates, long-acting formulations).
- By increasing reliable commercial supply, PolyPeptide reduces risk of drug shortages and supports global patient access.
- Technical innovations (higher purity, scalable synthesis) enable more complex peptide-based modalities to reach the clinic and market.
- Supply-chain resilience and regulatory readiness accelerate partner launches across major jurisdictions.
PolyPeptide Group AG (0AAJ.L) Vision Statement
PolyPeptide Group AG (0AAJ.L) envisions being the global leader in therapeutic peptides by delivering scalable, high-quality peptide active pharmaceutical ingredients (APIs) and peptide-based drug products through continuous innovation, operational excellence, and trusted partnerships. The vision centers on accelerating peptide therapeutics development and commercialization while expanding global manufacturing capacity and service offerings to meet growing market demand. Core Values- Innovation - relentless pursuit of new technologies, process improvements and digitalization across R&D and manufacturing to shorten development timelines and improve yields.
- Excellence - commitment to the highest quality standards in GMP manufacturing, regulatory compliance, and customer service to ensure product integrity and patient safety.
- Trust - building long-term, transparent relationships with pharma and biotech partners, regulators and stakeholders through reliable delivery, data integrity and ethical conduct.
- Capacity expansion: significant investments in multi-site scale-up and continuous manufacturing platforms to meet rising demand for complex peptides and ADC linker technologies.
- Technological advancement: adoption of automated peptide synthesis, high-throughput analytical platforms, and digital batch- and quality-management systems to raise throughput and reduce time-to-clinic.
- Customer-centric quality: extended technical services-process development, analytical support, formulation and fill-finish-anchored in GMP compliance to de-risk partners' clinical and commercial programs.
| Metric | Value | Reference Year / Note |
|---|---|---|
| Annual revenue | ~CHF 470 million | Most recent reported fiscal year (group level) |
| Adjusted EBITDA | ~CHF 120 million | Group reported adjusted EBITDA (latest FY) |
| Employees | ~1,700-2,000 | Global headcount across R&D and manufacturing sites |
| Manufacturing & R&D sites | 7+ global sites | Sites spanning Europe, North America and Asia |
| Customer base | 300+ pharma & biotech partners | Includes small biotech and large pharma collaborators |
| Capital investments (recent expansion tranche) | ~CHF 100-150 million | Multi-year capacity expansion and technology upgrades |
- Innovation: deployment of continuous-flow peptide synthesis lines and automated purification that reduced cycle times and cost per gram for select APIs.
- Excellence: maintenance of multiple GMP certifications and successful regulatory inspections, supporting rapid transfer from clinical to commercial supply.
- Trust: multi-year supply agreements and integrated development partnerships with leading biotech and pharma firms, reflected in recurring revenue streams.
- Revenue growth supports reinvestment in capacity and technology, enabling PolyPeptide to capture higher-value programs (longer peptides, conjugates, specialty APIs).
- Margins benefit from scale, operational excellence and higher-value service mix (process development, fill-finish), aiding adjusted EBITDA stability.
- Trust-driven partnerships lower customer attrition and create pipeline visibility, improving forecasting and capacity utilization rates.
PolyPeptide Group AG (0AAJ.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.